Knockdown of CD24 or Siglec10, as well as using CD24 monoclonal antibodies to block the interaction of CD24 with Siglec10, significantly enhances macrophage phagocytosis of all CD24-expressing human tumor cells. Here, SIGLEC10 is linked to neoplasm.